NCT00759928View on ClinicalTrials.gov

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2013

Study Completion Date

June 30, 2014

Conditions
Refractory Solid Tumors
Interventions
DRUG

Erlotinib

150 mg once daily by mouth

DRUG

Sorafenib

400 mg twice daily by mouth

Trial Locations (2)

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00759928 - PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter